Lactobacillus reuteri DSM 17938 in the Treatment of Functional Abdominal Pain in Children: RCT Study

Journal of Pediatric Gastroenterology and Nutrition

Volumn 64, Issue 6, 2017, Pages 925-929

  Jadrešin, Oleg ^a   Hojsak, Iva ^a   Mišak, Zrinjka ^a   Kekez, Alemka Jaklin ^b   Trbojević, Tena ^a   Ivković, Lana ^a   Kolaček, Sanja ^a  

^a Alergologiju I Reumatologiju S Klini kom Imunologijom   (Croatia)

^b Center for Pediatric Medicine helena   (Croatia)

Author keywords

children; functional gastrointestinal disorders; L reuteri DSM 17938; probiotics

Indexed keywords

PLACEBO; PROBIOTIC AGENT;

ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ADOLESCENT; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE DURATION; DOUBLE BLIND PROCEDURE; FACES PAIN SCALE; FECES; FEMALE; HUMAN; IRRITABLE COLON; LACTOBACILLUS REUTERI; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PAIN SEVERITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCHOOL ATTENDANCE; CHRONIC DISEASE; FOLLOW UP; PRESCHOOL CHILD; RECURRENT DISEASE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ABDOMINAL PAIN; ADOLESCENT; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; IRRITABLE BOWEL SYNDROME; LACTOBACILLUS REUTERI; MALE; PROBIOTICS; PROSPECTIVE STUDIES; RECURRENCE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 85000893980     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0000000000001478     Document Type: Article

References (52)

1. Chitkara DK, Rawat DJ, Talley NJ. The epidemiology of childhood recurrent abdominal pain inWestern countries: A systematic review. Am J Gastroenterol 2005;100:1868-75.
2. Di Lorenzo C, Colletti R, Lehmann H, et al. Chronic abdominal pain in children: A technical report of theAmerican Academy of Pediatrics and the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition: AAP Subcommittee and NASPGHAN Committee on Chronic Abdominal Pain. J Pediatr Gastroenterol Nutr 2005;40:249-61.
3. American Academy of Pediatrics, North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. Chronic abdominal pain in children. Pediatrics 2005;115:812-5.
4. Rasquin A, Di Lorenzo C, Forbes D, et al. Childhood functional gastrointestinal disorders: child/adolescent. Gastroenterology 2006;130:1527-37.
5. Simrén M, Barbara G, Flint HJ, et al. Intestinal microbiota in functional bowel disorders: A Rome foundation report. Gut 2013;62:159-76.
6. Chichlowski, Rudolph C. Visceral pain and gastrointestinal microbiome. J Neurogastroenterol Motil 2015;21:172-81.
7. Kovacic K. Current concepts in functional gastrointestinal disorders. Curr Opin Pediatr 2015;27:619-24.
8. Lee BJ, Bak YT. Irritable bowel syndrome, gut microbiota and probiotics. J Neurogastroenterol Motil 2011;17:252-66.
9. Whelan K. Probiotics and prebiotics in the management of irritable bowel syndrome: A review of recent clinical trials and systematic reviews. Curr Opin Clin Nutr Metab Care 2011;14:581-7.
10. Ford AC, Quigley EMM, Lacy BE, et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-Analysis. Am J Gastroenterol 2014;109:1547-61.
11. Moayyedi P, Ford AC, Talley NJ, et al. The efficacy of probiotics in the therapy of irritable bowel syndrome: A systematic review. Gut 2010;59:325-32.
12. Hoveyda N, Heneghan C, Mahtani KR, et al. A systematic review and meta-Analysis: probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterol 2009;9:15.
13. McFarland LV, Dublin S. Meta-Analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol 2008;14:2650-61.
14. Guandalini S, Cernat E, Moscoso D. Prebiotics and probiotics in irritable bowel syndrome and inflammatory bowel disease in children. Benef Microbes 2015;6:209-17.
15. Korterink JJ, Ockeloen L, Benninga MA, et al. Probiotics for childhood functional gastrointestinal disorders: A systematic review and metaanalysis. Acta Paediatr 2014;103:365-72.
16. Szajewska H, Setty M, Mrukowicz J, et al. Probiotics in gastrointestinal diseases in children: hard and not-so-hard evidence of efficacy. J Pediatr Gastroenterol Nutr 2006;42:454-75.
17. Vandenplus Y, Benninga M. Probiotics and functional gastrointestinal disorders in children. J Pediatr Gastroenterol Nutr 2009;48:S107-9.
18. Savino F, Cordisco L, Tarasco V, et al. Lactobacillus reuteri DSM 17938 in infantile colic: A randomized, double-blind, placebo-controlled trial. Pediatrics 2010;126:e526-33.
19. Szajewska H, Gyrczuk E, Horvath A. Lactobacillus reuteri DSM 17938 for the management of infantile colic in breastfed infants: A randomized, double-blind, placebo-controlled trial. J Pediatr 2013;162:257-62.
20. Sung V, Hiscock H, Tang ML, et al. Treating infant colic with the probiotic Lactobacillus reuteri: double blind, placebo controlled randomised trial. BMJ 2014;348:g2107.
21. Chau K, Lau E, Greenberg S, et al. Probiotics for infantile colic: A randomized double-blind placebo-controlled trial investigating Lactobacillus reuteri DSM 17938. J Pediatr 2014;166:74-8.
22. Coccorullo P, Strisciuglio C, Martinelli M, et al. Lactobacillus reuteri (DSM 17938) in infants with functional chronic constipation: A doubleblind, randomized, placebo controlled study. J Pediat 2010;157:598-602.
23. Romano C, Ferrau V, Cavataio F, et al. Lactobacillus reuteri in children with functional abdominal pain (FAP). J Paediatr Child Health 2014;50:E68-71.
24. Weizman Z, Blumin V, Abu-Abed J, et al. A randomized controlled trial of Lactobacillus reuteri DSM 17938 in functional abdominal pain of childhood. J Pediatr Gastroenterol Nutr 2014;58(suppl 1):109.
25. Eftekhari K, Vahedi Z, Kamali Aghdam M, et al. A randomized doubleblind placebo-controlled trial of Lactobacillus reuteri for chronic functional abdominal pain in children. Iran J Pediatr 2015;25:e2616.
26. Tomlinson D, Von Baeyer CL, Stinson JN, et al. A systematic review of faces scales for the self-report of pain intensity in children. Pediatrics 2010;126:e1168-9.
27. Koh H, Lee MJ, Kim MJ, et al. Simple diagnostic approach to childhood fecal retention using the Leech score and Bristol stool form scale in medical practice. J Gastroenterol Hepatol 2010;25:334-8.
28. Chumpitazi BP, Lane MM, Czyzewski DI, et al. Creation and initial evaluation of a Stool FormScale for children. J Pediatr 2010;157:594-7.
29. Gawronska A, Dziechciarz P, Horvath A, et al. A randomized doubleblind placebo-controlled trial of Lactobacillus GG for abdominal pain disorders in children. Aliment Pharmacol Ther 2007;25:177-84.
30. Dai C, Zheng CQ, Jiang M, et al. Probiotics and irritable bowel syndrome. World J Gastroenterol 2013;19:5973-80.
31. Hong SN, Rhee PL. Unraveling the ties between irritable bowel syndrome and intestinal microbiota. World J Gastroenterol 2014;20: 2470-81.
32. Si JM, Yu YC, Fan YJ, et al. Intestinal microecology and quality of life in irritable bowel syndrome patients. World J Gastroenterol 2004;10:1802-5.
33. Rajilić-Stojanović M, Biagi E, Heilig HG, et al. Global and deep molecular analysis of microbiota signatures in fecal samples frompatients with irritable bowel syndrome. Gastroenterology 2011;141: 1792-801.
34. Saulnier DM, Riehle K, Mistretta TA, et al. Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome. Gastroenterology 2011;141:1782-91.
35. Liebregts T, Adam B, Bredack C, et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology 2007;132:913-20.
36. Spiller R, Lam C. An update on post-infectious irritable bowel syndrome: role of genetics, immune activation, serotonin and altered microbiome. J Neurogastroenterol Motil 2012;18:258-68.
37. Chadwick VS, ChenW, Shu D, et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002;122:1778-83.
38. Barbara G, Stanghellini V, De Giorgio R, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004;126:693-702.
39. OMahony L, McCarthy J, Kelly P, et al. Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005;128:541-51.
40. Ma D, Forsythe P, Bienenstock J. Live Lactobacillus rhamnosus [corrected] is essential for the inhibitory effect on tumor necrosis factor alpha-induced interleukin-8 expression. Infect Immun 2004;72: 5308-14.
41. Rousseaux C, Thuru X, Gelot A, et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med 2007;13:35-7.
42. Kunze WA, Mao Y-K, Wang B, et al. Lactobacillus reuteri enhances excitability of colonic AH neurons by inhibiting calcium-dependent potassium channel opening. J Cell Mol Med 2009;13:2261-70.
43. Wang B, Mao Yk, Diorio C, et al. Lactobacillus reuteri ingestion and IKCa channel blockade have similar effects on rat colon motility and myenteric neurones. Neurogastroenterol Motil 2010;22:98-107.
44. Kamiya T, Wang L, Forsythe P, et al. Inhibitory effects of Lactobacillus reuteri on visceral pain induced by colorectal distension in Sprague-Dawley rats. Gut 2006;55:191-6.
45. McKernan DP, Fitzgerald P, Dinan TG, et al. The probiotic Bifidobacterium infantis 35624 displays visceral antinociceptive effects in the rat. Neurogastroenterol Motil 2010;22:1029-35.
46. Perez-Burgos A, Wang L, McVey Neufeld KA, et al. The TRPV1 channel in rodents is a major target for antinociceptive effect of the probiotic Lactobacillus reuteri DSM 17938. J Physiol 2015;593: 3943-57.
47. Guandalini S, Magazzu G, Chiaro, et al. VSL#3 improves symptoms in children with irritable bowel syndrome: A multicenter, randomized, placebo-controlled, double-blind, crossover study. J Pediatr Gastroenterol Nutr 2010;5:24-30.
48. Bausserman M, Michail S. The use of Lactobacillus GG in irritable bowel syndrome in children: A double-blind randomized control trial. J Pediatr 2005;147:197-201.
49. Francavilla R, Miniello V, Magista AM, et al. A randomized controlled trial of Lactobacillus GG in children with functional abdominal pain. Pediatrics 2010;126:e1445-52.
50. Saps M, Van Tilburg MA, Lavigne JV, et al. Recommendations for pharmacological clinical trials in children with irritable bowel syndrome: The Rome foundation pediatric subcommittee on clinical trials. Neurogastroenterol Motil 2016;28:1619-31.
51. Saps M, Youssef N, Miranda A, et al. Multicenter, randomized, placebocontrolled trial of amitriptyline in children with functional gastrointestinal disorders. Gastroenterology 2009;137:1261-9.
52. Kirsch I. Role of placebo in irritable bowel syndrome. J Pediatr Gastroenterol Nutr 2011;53(suppl 2):41-2.